Skip to content

Revenue at other companies

Cal-Maine Foods logo
Cal-Maine FoodsCALM
$666.95M-53.0%
Ollie's Bargain Outlet Holdings, Inc. logo
Ollie's Bargain Outlet Holdings, Inc.OLLI
$658.93M+14.2%
First BanCorp logo
First BanCorpFBP
$258.64M+4.2%
Henry Schein logo
Henry ScheinHSIC
$3.37B+6.3%
CSX logo
CSXCSX
$3.48B+1.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$246.09M+87.0%

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$3.42B+24.5%

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beam Therapeutics's revenue?
Beam Therapeutics (BEAM) reported revenue of $31.74M in Q1 2026.
How has Beam Therapeutics's revenue changed year-over-year?
Beam Therapeutics's revenue increased by 324.9% year-over-year, from $7.47M to $31.74M.
What is the long-term trend for Beam Therapeutics's revenue?
Over 4 years (2021 to 2025), Beam Therapeutics's revenue has grown at a 28.1% compound annual growth rate (CAGR), from $51.84M to $139.74M.